Forte Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 31.48 million compared to USD 13.88 million a year ago. Basic loss per share from continuing operations was USD 1 compared to USD 0.8 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7163 USD | -3.07% | -2.41% | -12.83% |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Camac Partners Provides Information to Shareholders | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.83% | 26.07M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023